Search Results
Your search for The A matches 32956 pages
Showing 12401 - 12450Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy in Early Breast Cancer
As reported in JAMA Oncology by Jayant S. Vaidya, MBBS, PhD, and colleagues, the phase III TARGIT-A trial showed that delayed second-procedure targeted intraoperative radiotherapy (TARGIT-IORT) was not noninferior to whole-breast external-beam radiotherapy (EBRT) in preventing local recurrence of...
Karen Wonders, PhD, on Benefits of Exercise During Cancer Treatment
Karen Wonders, PhD, of Wright State University, discusses the safety and efficacy of exercise during cancer treatment in minimizing toxicities and addressing the short- and long-term effects of cancer therapy. Dr. Wonders suggests that exercise becomes a standard of care for patients with cancer...
Differences in Melanoma Incidence in Men vs Women by Age and Anatomic Site
In a study published by Olsen et al in JAMA Dermatology, researchers found that in predominantly fair-skinned populations, melanoma incidence differed by age and anatomic site in men and women. Methods A cross-sectional analysis of sex- and site-specific trends was performed for white patients...
Neoadjuvant Immunotherapy in Early-Stage Colon Cancer
Patients with localized colon cancer may benefit from a short course of neoadjuvant immunotherapy, according to findings from the exploratory phase II NICHE study published by Myriam Chalabi, MD, and colleagues in Nature Medicine. Study Results Forty patients with two colon cancer subtypes—either ...
ASCO Releases New Guidance on Allocation of Limited Resources in the Oncology Community During COVID-19 Pandemic
ASCO has released a set of recommendations to support the oncology community as health-care institutions across the United States face potentially difficult decisions around the allocation of scarce health-care resources during the COVID-19 pandemic. In some geographic areas, the ongoing crisis is...
Postdiagnosis Weight and Mortality in Survivors of Nonmetastatic Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Troeschel et al found that postdiagnosis obesity was associated with higher cardiovascular disease mortality and all-cause mortality, and postdiagnosis weight gain was associated with higher all-cause and prostate cancer–specific mortality in ...
Activity of Pembrolizumab in Patients With NSCLC Brain Metastases
As reported in The Lancet Oncology by Sarah B. Goldberg, MD, MPH, and colleagues, continued follow-up of the non–small cell lung cancer (NSCLC) cohort of a single-institution phase II trial showed that pembrolizumab produced responses in patients with brain metastases and programmed cell death...
Report on the ASH COVID-19 Registry for Malignant Hematology
We begin with an interview with William A. Wood, MD, MPH, of the University of North Carolina, Chapel Hill. Dr. Wood is current Chair of the ASH Research Collaborative’s Data Hub Oversight Group, and he spoke with us about the new COVID-19 Registry for Malignant Hematology. Next, we’ll move onto a...
William J. Gradishar, MD, on Innovating Pathways for Patient Self-Management in Breast Cancer
William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the “4R Model” (Right Information, Care, Patient, and Time) which has proved to be a promising method for patient self-management. Patient care sequence plans markedly improved several...
FDA Pipeline: Priority Reviews for Immunotherapy Based on Biomarker Status, Combination First-Line Therapy in Lung Cancer
Over the past week, the U.S. Food and Drug Administration (FDA) granted Priority Review to an immunotherapeutic agent for solid tumors with a high tumor mutational burden and to a combination treatment for the first-line treatment of metastatic or recurrent non–small cell lung cancer. The agency...
ASCO’s New COVID-19 Cancer Registry Aims to Understand Impact on Patients During Pandemic, Inform Future Care
On April 10, ASCO launched the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry) to help the entire cancer community learn about the pattern of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 infections impact the delivery of cancer care and patient...
NCCN Issues Guidance on Improving COVID-19 Safety for Patients and Health-Care Providers
The National Comprehensive Cancer Network’s® (NCCN®) Best Practices Committee has published a preprint article in JNCCN—Journal of the National Comprehensive Cancer Network detailing their recommendations for keeping patients with cancer, as well as their caregivers and health-care staff, as safe...
‘Textbook Outcome’ in Patients Undergoing Resection of Pancreatic Neuroendocrine Tumors
In a study reported in the Journal of Surgical Oncology, Timothy M. Pawlik, MD, MPH, PhD, and colleagues found that approximately half of patients undergoing resection of pancreatic neuroendocrine tumors (PNETs) had a “textbook outcome”—a result associated with significantly improved disease-free...
Outcomes of COVID-19 Infection in Patients With Cancer in Wuhan, China
In a retrospective cohort study reported in the Annals of Oncology, Li Zhang, MD, of the Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, and colleagues described characteristics and outcomes of COVID-19 infection in 28 patients with cancer from...
FDA Approves Selumetinib for Pediatric Patients With NF1 and Symptomatic Inoperable Plexiform Neurofibromas
On April 10, the U.S. Food and Drug Administration (FDA) approved selumetinib (Koselugo) for pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic inoperable plexiform neurofibromas. Selumetinib, a kinase inhibitor, is the first therapy approved for...
Trusted Patient Resource: ASCO Answers Fact Sheet on Fertility and Cancer Treatment
Cancer and its treatment can cause infertility in both men and women. Educate your patients about this potential side effect by giving them the ASCO Answers fact sheet Your Fertility and Cancer Treatment. This fact sheet covers: An overview of what the terms fertility and infertility mean What...
Lawrence Einhorn, MD, FASCO, Reflects on the Path to a Cure
Cancer.Net, ASCO’s patient information website, reports a current survival rate for stage I testicular cancer at 99%, but in 1974, men faced an overall survival rate of 5%. Surgery was the only viable treatment option, and if it failed, the prognosis was fatal. Lawrence Einhorn, MD, FASCO, was a...
House Bill Supports Innovative Payment Models, While Protecting People With Cancer and Their Providers
In a letter to Representatives Terri Sewell (AL), Adrian Smith (NE), Tony Cárdenas (CA), and John Shimkus (IL), the Association for Clinical Oncology conveyed its support for legislation the lawmakers introduced in the U.S. House of Representatives. The bill—H.R. 5741, or the Strengthening...
Significant Changes to Evaluation and Management Codes in 2021—Start Preparing Now
Starting January 1, 2021, there will be significant changes to the office and outpatient Evaluation and Management services Current Procedural Terminology codes (99202–99215) for both new and established patients. Practices, physicians, and staff must prepare in advance for these changes to ensure...
R. Kate Kelley, MD: Breakthroughs for Hepatocellular Carcinoma
At the University of California, San Francisco School of Medicine, R. Kate Kelley, MD, contributes to research focused on improving outcomes for patients with hepatocellular carcinoma. The trial: This was a phase III study that included 707 patients who received sorafenib and had disease...
From a Single Course, a Far-Reaching Impact Across the Region
It was a great honor for the Russian Society of Clinical Oncology (RUSSCO) to collaborate on the ASCO IPCW, and for me to be a co-organizer of the event from the Russian side. RUSSCO is a professional cancer society with the mission to advance cancer treatment and cures. The organization...
International Palliative Care Workshop in Russia Educates Providers, Improves Care Across Region
ASCO, in collaboration with international oncology societies, hosts International Palliative Care Workshops (IPCWs) designed to teach participants practical skills in patient communication and the management of cancer symptoms and pain. The IPCWs are led by ASCO member volunteers and local experts...
Breast Cancer Specialist Lawrence J. Solin, MD, FACR, FASTRO, Dies at Age 66
Lawrence J. Solin, MD, FACR, FASTRO, a champion of breast-conserving therapy for women with breast cancer, died unexpectedly on March 3 at the age of 66. At the time of his death, Dr. Solin was Professor Emeritus, Department of Radiation Oncology, Perelman School of Medicine, University of...
Living A Full Life After Pancreatic Cancer
I have been a radiologic technologist for 47 years, so after going to the bathroom one Sunday morning in October 2018 and finding my urine had suddenly turned dark, I knew something was wrong. I wasn’t in any pain and did not have a urinary tract infection, which would explain the discoloration of...
City of Hope Deploys Platform, Makes Study Data Accessible
A $12 million federal grant enabled City of Hope and collaborators to deploy a novel cloud-computing platform, making an immense amount of data from a historic 25-year study more accessible and user-friendly. The ongoing California Teachers Study, which began in 1995, has already given researchers...
A Hallmark Moment
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
What’s in a Name?
When Narjust Duma, MD, Assistant Professor of Medicine and a thoracic oncologist at the University of Wisconsin Carbone Cancer Center in Madison, presented the findings from her study, “Evaluating Unconscious Bias During Speaker Introductions at an International Oncology Conference,” during the...
Using Respectful Language to Reduce Unconscious Bias in Oncology Care
An abstract presented at the 2019 ASCO Annual Meeting titled “Evaluating Unconscious Bias During Speaker Introductions at an International Oncology Conference,” by Narjust Duma, MD, Assistant Professor of Medicine and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center in...
Highlights From Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
The Combined Annual Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) were held in Orlando, Florida, from February 19–23, 2020. The scientific program addressed the most timely issues in ...
Donald Sullivan, MD, Receives ATS Foundation Research Program/American Lung Association Partner Grant
The ATS Foundation Research Program and the American Lung Association have awarded Donald Sullivan, MD, of Oregon Health & Science University, a $100,000 Foundation Partner grant. The grant will help support Dr. Sullivan’s research project, which he said will “answer important knowledge gaps...
Philadelphia T-Cell Lymphoma/Leukemia Initiative to Be Launched
The Sidney Kimmel Cancer Center–Jefferson Health (SKCC) will establish the Philadelphia T-Cell Lymphoma/Leukemia Initiative to map and address knowledge gaps related to T-cell lymphoma and leukemia (TCLL), unmet patient needs, and barriers to progress in the existing TCLL care model. Pierluigi...
Updates From Selected Clinical Trials in Breast Cancer
Each year, The ASCO Post asks Jame Abraham, MD, FACP, Chairman of the Department of Hematology and Medical Oncology at Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, to offer his picks for the most important research presented at 2019 San...
MSK and City College of New York Researchers Awarded $15 Million Grant From NCI
Francesca Gany, MD, MS, Chief of the Immigrant Health and Cancer Disparities Service, and Tim Ahles, PhD, Director of the Neurocognitive Research Laboratory, both of Memorial Sloan Kettering Cancer Center (MSK), along with Gilda Barabino, PhD, and Karen Hubbard, PhD, of the City College of New York ...
Inspired by Her Physician Father, Reshma Jagsi, MD, DPhil, Tirelessly Advocates for Women’s Health and Careers in Medicine
Physician-scientist, Reshma Jagsi, MD, DPhil, was encouraged by her parents to become a politically active, socially conscious citizen of the world. “As a young woman, my mother traveled from Africa on a scholarship to the United States, where she attended the University of Wisconsin. It was in the ...
Expert Point of View: Timothy A. Yap, MBBS, PhD, FRCP
Semaphorin 4D (SEMA4D, and its receptor, plexin B1) is broadly expressed in malignant tumors. Aside from other “normal functions” in tumors, SEMA4D influences the infiltration and distribution of leukocytes into the microenvironment, and its inhibition promotes functional immune infiltration....
SEMA4D Inhibition: A Novel Means of Improving Immune Response
A novel class of inhibitors may hold some promise for boosting responses to checkpoint inhibitors and for sensitizing poorly immunogenic tumors, such as pancreatic cancer, to immunotherapy. The drug targets semaphorin 4D (SEMA4D), a glycoprotein expressed on the cell membranes of many tumor types....
Expert Point of View: Jarushka Naidoo, MBBCh
Discussant of the abstract on antibiotic exposure, Jarushka Naidoo, MBBCh, Assistant Professor of Oncology and Attending Physician at the Sidney Kimmel Cancer Center at Johns Hopkins University, said that Mr. Chu and colleagues have added to the recent literature examining concurrent use of...
Prior Antibiotic Use Linked to Poorer Survival in Patients With Advanced Melanoma Receiving Immune Checkpoint Inhibitors
Treatment with antibiotics prior to immune checkpoint inhibitor therapy may confer poorer overall survival and an increased risk of colitis in patients with advanced melanoma, according to data presented at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.1 The largest institutional...
Should Restrictions on Genetic Testing Be Loosened?
The loosening of restrictions on genetic testing would mean that all health-care providers could help move this needle to where it should be, according to Kevin S. Hughes, MD, a surgeon at Massachusetts General Hospital, Professor of Surgery at Harvard Medical School, and Medical Director of the...
ASCO Board Concludes Annual Meeting Cannot Occur in Person
On March 24, 2020, ASCO issued the following statement: ASCO’s primary concern is the health and safety of the global oncology community and the patients we serve. As public health safety measures related to COVID-19 extend, the ASCO Board has concluded that the Annual Meeting, scheduled for May 29 ...
Pembrolizumab Plus Radiotherapy Worthy of Further Study in Locally Advanced Squamous Cell Head and Neck Cancer
The combination of the checkpoint inhibitor pembrolizumab and definitive radiation therapy appears to be a safe and feasible option for patients with locally advanced head and neck cancer who are not eligible for cisplatin, according to data presented at the 2020 Multidisciplinary Head and Neck...
Expert Point of View: Tanguy Y. Seiwert, MD
Moderator of the session, Tanguy Y. Seiwert, MD, Director of the Head and Neck Cancer Oncology Disease Group and Assistant Professor of Oncology at Johns Hopkins University, in Baltimore, underscored the “dramatically good” preclinical data supporting the use of mTOR inhibitors in advanced...
Study Suggests Adjuvant Everolimus May Benefit Patients With Advanced Head and Neck Cancer
The mTOR inhibitor everolimus, used to treat breast and kidney cancers, may benefit patients with advanced squamous cell carcinoma of the head and neck, according to data presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium.1 The results of an investigator-initiated, phase II...
ASCO Releases Resource-Stratified Guideline on the Treatment of Late-Stage Colorectal Cancer
ASCO has released a new guideline for clinicians and policymakers in resource-constrained settings on treating patients with late-stage colorectal cancer.1 “Around the world, there is a huge variation in resources, and what is available to clinicians may change week to week,” said Mary D....
Immunotherapy ‘Comes of Age’ in Breast Cancer
Immunotherapeutics in breast cancer will likely not be limited to late-stage triple-negative breast cancer. Earlier lines, combination regimens, and expansion into different disease subtypes should become part of this emerging landscape, according to Hope S. Rugo, MD, FASCO, Professor of Medicine...
Nancy E. Davidson, MD, on COVID-19 and Cancer Care: Thoughts From the Seattle Epicenter
Nancy E. Davidson, MD, of the Seattle Cancer Care Alliance, and a member of The ASCO Post Editorial Board, talks about her experiences in one of the communities hardest hit by coronavirus and offers some practical advice on making changes in treatment and research. Recorded April 7, 2020.
T-Cell Responses and Benefit From Treatment With Ipilimumab in Patients With Metastatic Castration-Resistant Prostate Cancer
Although patients with metastatic castration-resistant prostate cancer typically have limited responses to immunotherapy, a subset of patients with pretreatment evidence of active T-cell responses in their tumors experienced prolonged survival following treatment with ipilimumab in a phase II...
New Prognostic Score for Asymptomatic Patients With Early-Stage CLL
A new prognostic tool may help to predict time to first treatment for patients with early-stage, asymptomatic chronic lymphocytic leukemia (CLL). Researchers described what they hope will become a point-of-care resource to help improve clinical decision-making in a study published by Rossi et al in ...
Factors Associated With Early Readmissions to Hospital Oncology Services
In a study reported in JCO Oncology Practice, Zibelli et al found that patients with cancer readmitted to hospital within 30 days from index admission often made the decision to return to hospital themselves, without input from their care teams. Study Details The study included 33 patients...
PSA Levels Before Salvage Radiotherapy and Outcomes With Long-Term Antiandrogen Therapy in Prostate Cancer
In an analysis from the NRG/RTOG 9601 trial reported in JAMA Oncology, Daniel E. Spratt, MD, and colleagues found that higher prostate-specific antigen (PSA) pre–salvage radiotherapy (SRT) levels after prostatectomy were associated with better overall survival vs lower levels in men with prostate...
